Arca
Skip to content

Lupus erythematosus

Drug research and approvals for lupus erythematosus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 296 studies of lupus erythematosus are recruiting on ClinicalTrials.gov, Health Canada has authorized 51 drug trials for it since 2013, FDA has 0 approved and 3 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 296
  • Trials authorized in Canada: 51
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 296 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 51; search them all in Canada trials
Jul 30, 2026A phase 3, single-arm, open-label, long-term extension study to evaluate the safety and efficacy of enpatoran in participants with active cutaneous…ENPATORAN (E5049, M5049)Merck KGaAPending
Mar 20, 2026A phase 3, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of enpatoran in participants with active cutaneous…ENPATORAN (M5049)Merck KGaAPending
Mar 20, 2026A phase 3, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of enpatoran in participants with active cutaneous…ENPATORAN (M5049)Merck KGaAPending
Jan 20, 2026Multinational, interventional, 52-week, open-label, single-arm study to evaluate the treatment outcomes of anifrolumab 120 mg subcutaneous once weekly in…ANIFROLUMAB (MEDI-546)AstraZeneca Pharmaceuticals LPOngoing
Dec 23, 2025Phase 1b/2 study of azd0120, a chimeric antigen receptor t-cell (car t) therapy targeting cd19 and b-cell maturation antigen (bcma) in subjects with refractory…AZD0120 (GC012F)AstraZeneca Pharmaceuticals LPPending
Aug 1, 2025A phase 2, multicenter, open-label study of cc-97540 (bms-986353), cd19-targeted nex-t car t cells, in participants with active sle (including lupus nephritis)…BMS-986353 (CC-97540)Bristol-Myers SquibbOngoing
Jun 25, 2025A phase 2b, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of imvt-1402 in participants with active…IMVT-1402IMMUNOVANT SCIENCES GMBHClosed
Apr 3, 2025Open-label, phase 1 study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of azd5492 folllowing single-ascending dose and step-up…AZD5492AstraZeneca Pharmaceuticals LPOngoing
Dec 17, 2024A phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus…YTB323 (RAPCABTAGENE AUTOLEUCEL) / FLUDARABINE PHOSPHATE / CYCLOPHOSPHAMIDENovartis Pharmaceuticals CorporationPending
Nov 14, 2024A phase I study to evaluate the safety and preliminary efficacy of ata3219, allogeneic anti cd19 chimeric antigen receptor t cell (car t) therapy, in subjects…ATA3219 / FLUDARABINE PHOSPHATE / CYCLOPHOSPHAMIDE / METHYLPREDNISOLONE SODIUM…Atara BiotherapeuticsPending

FDA Orphan Designations

Approved first, then open designations, newest first
Feb 9, 1999Humanized MAb (IDEC-131) to CD40LTreatment of systemic lupus erythematosus.Biogen IdecInc.Designated
Feb 18, 1998Recombinant humanized monoclonal antibody 5c8Treatment of systemic lupus erythematosus.Biogen, Inc.Designated
Jul 13, 1994DehydroepiandrosteroneTreatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.GlaxoSmithKlineDesignated

Medicines Authorised in the EU

Newest first
Feb 14, 2022SaphneloanifrolumabAstraZeneca ABEMA ↗
Jul 13, 2011BenlystabelimumabGlaxoSmithKline (Ireland) LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.